http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108721243-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate | 2017-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108721243-B |
| titleOfInvention | Crizotinib pharmaceutical composition and preparation method thereof |
| abstract | The invention belongs to the field of pharmaceutical preparations, and relates to a crizotinib pharmaceutical composition and a preparation method thereof. The pharmaceutical composition of the present invention reduces the dosage of auxiliary materials, is convenient to take, and is beneficial to improving patient compliance; and the pharmaceutical composition of the present invention is safe and stable, and has good dissolution rate. The preparation method of the crizotinib pharmaceutical composition provided by the invention is easy to operate, has no solvent residue, and is suitable for industrial production. |
| priorityDate | 2017-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.